NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCBB: RBCC) announced today that its joint venture partner, drug delivery innovator TheraKine, reached an exciting new research milestone that could soon lead to big profits. TheraKine is dedicated to developing an injectable, sustained-release technology that will allow any biological drug to be formulated for months of stable, controlled release. It’s a platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before, and the technology took a big step closer to entering the healthcare market this week.
Help employers find you! Check out all the jobs and post your resume.
